ANTIBODIES TO HUMAN NKG2D AND THEIR APPLICATION Russian patent published in 2015 - IPC C07K16/28 C12P21/08 A61K39/395 A61P37/06 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of biotechnology and immunology. Described are separated monoclonal antibody and its antigen-binding fragment, which bind hNKG2D and cross-link not more than two hNKG2D dimers when added to NK or T cells, which express NKG2D, which include: heavy chain CDR1, containing SYYWS; heavy chain CDR2, containing HISYSGSANYNPSLKS; and heavy chain CDR3, containing WDDAFNI; and light chain CDR1, containing RASQSVSSSYLA; light chain CDR2, containing GASSRAT; and light chain CDR3, containing QQYGSSPWT. Claimed is method of obtaining said anti-NKG2D antibody or its antigen-binding fragment, which includes cultivation of host cells, containing nucleic acid, which codes said antibody or its antigen-binding fragment, at suitable conditions and extraction of claimed antibody or its antigen-bonding fragment. Disclosed is method of treatment or prevention of inflammatory or autoimmune disorder by reduction or inhibition of hNKG2D-mediated activation of NK or T cells, where inflammatory or autoimmune disorder is caused or is characterised by increased activity of NK or T cells, which includes introduction of said antibody or antigen-binding fragment to individual, suffering from such inflammatory or autoimmune disorder.

EFFECT: invention makes it possible to block hNKG2D-MICA-mediated activation of NK or T cells, which express NKG2D, by prevention of binding of two monomers of NKG2D dimmer with MICA.

10 cl, 22 dwg, 15 tbl, 12 ex